Oppenheimer Maintains Outperform on ResMed, Raises Price Target to $205
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Suraj Kalia has maintained an Outperform rating on ResMed (NYSE:RMD) and increased the price target from $185 to $205.

January 30, 2024 | 6:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Suraj Kalia reaffirmed an Outperform rating on ResMed and raised the price target to $205, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst typically suggests a bullish outlook on the stock, reflecting expectations of strong performance or positive developments. Investors often view such updates as a sign of confidence in the company's future prospects, which can lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100